Aurobindo Pharma schedules 39th AGM for Aug 27 via VC
NiveshIQ
NSE: AUROPHARMA · Pharma
Aurobindo Pharma Ltd.
₹1,590.70▲ ₹41.50 (+2.68%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on AUROPHARMA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Aurobindo Pharma Ltd.
Aurobindo Pharma Limited is a biopharmaceutical company that develops, manufactures, commercializes, and sells generic pharmaceuticals, APIs, and injectables across various therapeutic areas. The company offers a diverse portfolio of products, including oral solids, liquids, injectables, vaccines, and metered dose inhalers, as well as APIs, biosimilars, and peptides. With operations in India, the United States, Europe, Puerto Rico, and internationally, Aurobindo Pharma has established itself as a significant player in the global healthcare industry. The company's recent developments, including the receipt of OAI classification from the FDA for its Telangana facility, demonstrate its commitment to quality and regulatory compliance. Despite facing scrutiny from the FDA, Aurobindo Pharma has
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹29,002 Cr +16.70% | ₹31,724 Cr +9.40% | ₹33,653 Cr +6.10% |
| EBITDA Margin | 20.09% | 20.65% | 21.80% |
| Net Profit | ₹3,169 Cr +64.40% | ₹3,484 Cr +9.90% | ₹3,567 Cr +2.40% |
| EPS | ₹54.15 | ₹60.02 | ₹60.34 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Aurobindo Pharma Q1 Results: Earnings call scheduled for Aug 6
Stocks to watch on Monday: NBCC, NTPC, Aurobindo Pharma, Waaree Energies, Cyient, Dodla Dairy and more
🔒
+ 3 more stories about Aurobindo Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹8, 853 Cr, PAT ₹921 Cr, EPS ₹15.86, EBITDA margin 21.1%. Growth context: revenue YoY +5.6%, PAT YoY +2.0%, revenue QoQ +2.4%, PAT QoQ +1.2%. Street verdict: inline, revenue surprise +0.6%, PAT surprise -1.1%.
Management's near-term growth strategy hinges on product launches, approvals, and therapy-mix improvement, complemented ...
FY26 (last completed FY): revenue ₹33, 653 Cr, PAT ₹3, 567 Cr, EBITDA margin 21.8%, EPS ₹60.34. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for AUROPHARMA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track AUROPHARMA alongside your other holdings
Unlock full AUROPHARMA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Aurobindo Pharma Ltd.?
NiveshIQ detects active intelligence signals for Aurobindo Pharma Ltd. (AUROPHARMA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Aurobindo Pharma Ltd.?
Aurobindo Pharma Ltd. operates in the Pharma sector with a market capitalisation of ₹8,625,484.6L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.